melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling
Melior Discovery
home
Our Services
High Throughput In Vivo Pharmacology:
Our Technology
 
 

theraTRACE

Melior Pharmaceuticals

  

               

 

 

              

    

 

                

 

 

 

 

 

melior melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling

Melior Discovery testimonials

“…to evaluate our lead compound in an EEG-based sleep wake model. Melior’s very experienced team provided valuable insights and recommendations on study design, analysis and interpretation of the data. As a virtual company, Prexa relied on Melior to become an extension of our knowledge team and they met all our expectations."

-Pat Baskin and Ev Graham

Prexa Pharmaceuticals

 

"Having worked with Melior quite extensively over the past several years, we find the team to be highly knowledgeable, responsive and adaptable to our needs. The overall process has been highly efficient and we are impressed by the quality of their reports."
- Christopher Prior, Ph.D., CEO,
PhaseBio Pharmaceuticals Inc.

                                

"Addex Therapeutics has been collaborating with Melior Discovery for more than a year. The studies performed at Melior are always carefully planned and skilfully executed while the progress of the project is well-tracked and communicated to the customer. On several occasions, when testing our compounds in a new in vivo assay, we relied on Melior's scientists in their guidance and advice. We have been particularly pleased with a series of experiments involving assessment of compounds' profiles in the rat sleep/wake EEG. This approach, that has a translational relevance, offered a sensitive measure of a compound's efficacy and side-effects."
- Mikhail Kalinichev, Ph.D., Associate Research Director,
Addex Therapeutics

                                

“Melior provided state-of-the-art preclinical pharmacology support for a period of nearly a year, where a series of in vivo studies were completed on a weekly basis. The staff was extremely user-friendly and the operational processes were excellent. I can recommend Melior without reservation.”
– Richard DiMarchi, PhD
Cox Professor of Chemistry & Gill Chair in Biomolecular Sciences
Indiana University, Department of Chemistry

 

“Melior is more than just a service company.  Their experienced staff guided us in our drug development efforts.  We consider Melior an extension of our own research team.”
- Josh Schultz,
Carolus Therapeutics

 

“[We] have been impressed with [Melior’s] ability to rapidly and effectively evaluate compounds in animal models…as we strive to identify compounds to ameliorate the devastating symptoms of Rett,”
- Monica Coenraads, Executive Director,
Rett Syndrome Research Trust

 

“I have been working with Melior on a number of projects over the course of a few years now.  They have been a great partner throughout this time.  The scientists whom I have worked with have been great problem-solvers and were customer focused.”
- Jay Lichter,
Avalon Ventures

 

“We chose Melior Discovery because they were responsive and cost effective.  We are staying with them as a chosen scientific partner because of their thoughtful scientific input to experimental design and attention to detail.  Their expertise and flexibility allowed us to quickly adapt the study design and evaluate additional outcome measures to pursue unexpected activity.” 
- Sridharan Rajamani, Ph.D.,  Senior Research Scientist,
Gilead Sciences

 

For additional information, contact:
Andrew G. Reaume
President and CEO, Co-Founder
(610) 280-0633 ext. 239

 

Back to top of page